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S306 Poster Session IIup time of 6.5 months, one patient died of disease relapse (ALL),
Two patients died of acute GVHD and 7 patients are alive without
evidence of leukemia. CPX-351 followed by RIC SCT is feasible,
and further dose escalation and schedule adjustment to define
MTD is ongoing. Remission status is not a prerequisite for a success-
ful outcome in selected patients.418
HIGHER BUSULFAN DOSE INTENSITY DOES NOT IMPROVE OUTCOMES
OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANS-
PLANTATION (AHCT) FOLLOWING FLUDARABINE/BUSULFAN/ATG (FBA)-
BASED REDUCED TOXICITY CONDITIONING (RTC)
Hamadani, M.1, Craig, M.1, Abraham, J.1, Tse, W.1, Cumpston, A.1,
Gibson, L.F.1, Remick, S.C.1, Leadmon, S.1, Elder, P.2, Hofmeister, C.2,
Penza, S.2, Andritsos, L.2, Blum, W.2, Benson DM Jr.2, Devine, S.M.2
1West Virginia University, Morgantown, WV; 2The Ohio State
University, Columbus, OH
We evaluated the impact of busulfan dose-intensity in patients un-
dergoing RTC AHCT in a multicenter retrospective study of 112
consecutive patients. Seventy-five patients were conditioned with
busulfan (0.8 mg/kg/dose IV x 8 doses [6.4mg/kg total dose]), fludar-
abine (30mg/m2/day, days -7 to -3), and 6mg/kg of ATG (L-FBA
group), while 37 patients received a more-intense RTC with busul-
fan (130mg/m2/day IV, days -6 to -3 [12.8mg/kg total dose]), fludar-
abine (40mg/m2/day, days -6 to -3), and 6mg/kg of ATG (H-FBA
group). At baseline (see Table 1.) the L-FBA and H-FBA groups
were matched for median age (58yr vs. 55yr; p5 0.3), unrelated do-
nor allografts (88% vs. 75%; p 5 0.1), and HLA-mismatched allo-
grafts (22% vs. 21%; p 5 0.9). More patients in L-FBA group had
high-risk disease (88% vs. 75%; p 5 0.01), higher median HCT-
CI (2 vs. 1; p 5 0.01) and better KPS (90 vs. 80; p 5 0.001).
Table 1. Baseline Characteristics of Patients Undergoing RTC
with FBA
L-FBA [N575] H-FAB [N537] p-ValueAge (median) 58 years 55 years 0.3
Unrelated Donors 66 (88%) 28 (75%) 0.1
High-risk Disease* 66 (88%) 25 (67%) 0.01
Diagnosis
AML/ALL 28% 43% 0.1
MDS 12% 21% 0.18
NHL/Hogkin’s Lymphoma 24% 21% 0.77
CLL/CML 34% 8% 0.002
Others 1.3% 5.4% 0.2
KPS (median) 90 80 0.001
HCT-CI (median) 2 1 0.01
HLA-mismatched transplants 17 (22%) 8 (21%) 0.9
Follow-up (surviving pts;
median)404 days 378 days 0.2*High-risk per standard CIBMTR criteria. HCT-CI, Hematopoietic cell
transplantation comorbidity index; KPS, Karnofsky performance score.
GVHD prophylaxis consisted of micro-dose methotrexate/ calci-
neurin inhibitor combination. There were no graft rejections. Me-
dian time to neutrophil (16days vs. 17days; p 5 0.03) and platelet
engraftment (14days vs. 16days; p 5 0.0001) was significantly faster
in H-FBA group. Compared to patients receiving H-FBA, those re-
ceiving L-FBA had fewer bacterial infections (56% vs. 32%; p-value
5 0.01), similar CMV reactivations (p5 0.6) and more EBV reacti-
vations (0% vs. 16%; p 5 0.001). For L-FBA and H-FBA groups
rates of grade II-IV acute GVHD (41% vs. 47%; p-value 5 0.68),
and chronic GVHD (35% vs. 46%; p-value5 0.21) were not signif-
icantly different. In similar order at 1-year the cumulative-incidence
of non-relapse mortality (NRM) (11% vs. 22%; p-value 5 0.2) and
relapse rates (37% vs. 40%; p5 0.8) were not significantly different.
The median follow-up of surviving patients is 14 months. Patients in
L-FBA and H-FBA groups had similar 1-year overall survival (61%
vs. 50% p5 0.1) and progression free survival (51% vs. 36% p-value
5 0.3). Our data suggest that merits of higher busulfan dose-inten-
sity in the context of FBA-based RTC may be offset by slightlyincreased early morbidity and NRM, suggesting prospective trials
are warranted.
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THE NUMBER OF CD34+ CELLS IN PERIPHERAL BLOOD PRE LEUKAPHE-
RESIS OF ALLOGENEIC STEM CELL DONORS IS RELATED TO DONOR
DEMOGRAPHIC AND HEMATOLOGIC FACTORS ON THE DAY OF COLLEC-
TION. RESULTS OF A SINGLE CENTER STEM CELL COLLECTION
VALIDATION STUDY
Baron, C., Ahmad, I., Busque, L., Cohen, S., Depeault, L., Lachance, S.,
Roy, D.C., Roy, J., Sauvageau, G., Kiss, T.L. Maisonneuve Rosemont
Hospital, University of Montreal, Montreal, QC, Canada
Introduction: Leukapheresis has become the preferred tool of stem
cell collection for allogeneic transplants. CD34 cell count per ml in
peripheral blood on the day of collection can be used to estimate col-
lection yield. CD34 counts show variability related to donor specific
factors. We have identified in this study predictive factors influenc-
ing CD34 cell count and collection yield in a homogenous cohort of
donors.
Methods: 269 collections were performed in 217 consecutive alloge-
neic stem cell transplant donors in the pheresis unit of Maisonneuve
Rosemont Hospital between 2006 and 2009. Median age was 50
years (22-76). 99 (46%) were female. G-CSF was used at a dose of
5mg/kg BID for 4 days. Collections were initiated at a level of 10
CD34 cells/ml on day 5 using a Cobe Spectra pheresis device.
Results:Median blood volume cycled was 15.9 liters (5-20). 174 do-
nors (80%) required one collection to achieve a graft of 5x106/kg, 43
required additional collections. Median CD34 count/ml was 71 (4.5-
378.5). Male had a higher CD34 count/ml on all days of collection as
female donors (95 versus 73 CD34/ml, p5 0.001). Women and men
above the age of 55 had lower CD34 counts/ml as compared to youn-
ger donors (women: 94 versus 74, p5 0.022; men: 113 versus 83, p5
0.013). More female than male donors required multiple collections
to achieve a satisfactory graft (27 versus 14%, p\0.01). There were
statistically significant positive correlations between total leucocyte
(lc), mononuclear cell (MNC), platelet (plt) and CD34 counts/ml
measured in the peripheral blood. No correlation between hemoglo-
bin and CD34 count was noted. A median of 4.8x108 CD34 + cells
were collected per graft (0.2-19.5). A significant positive correlation
was noted between collection yield and pre collection total lc, MNC,
plt, CD34 /ml and total lc count in the graft. The median collection
efficiency (CE) for the whole cohort was 42%.We observed a signif-
icantly higher CE using a manual mode of collection as compared to
an automatic mode (46 vs 29%, p\ 0.001).
Conclusions: CD34 cell count pre collection is affected by donor
age and gender. A higher proportion of female donors require mul-
tiple collections. A number of haematological parameters are corre-
lated with an elevated CD34 count in peripheral blood on the day of
collection.These factors help determine donors at higher risk of a de-
creased yield of stem cell collection. A manual mode of collection
appears to lead to superior collection efficiency.420
THE ROLE OF AMD3100 AS A PREPARATIVE REGIMEN IN ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION
Ko, R.M., Logronio, K., Czechowicz, A., Shizuru, J.A. Stanford Univer-
sity, Palo Alto, CA
Since the development of allogeneic hematopoietic cell transplan-
tation (HCT),many advances have beenmade that allowHCT treat-
ment to be utilized in a wider range of patients. In the face of all these
developments, additional barriers to engraftment have emerged. In
addition to the immune barrier, non-immune related barriers are
thought to contribute to engraftment resistance. One physical bar-
rier of HCT engraftment is a need for space in the host hematopoi-
etic stem cell (HSC) niche. It has been suggested that donor cells
must home to specific areas in the bone marrow, engraft, and prolif-
erate in these spaces. If endogenous HSCs occupy the niche, it is hy-
pothesized that incoming donor cells will not be able to engraft.
AMD3100 is a small molecule antagonist of CXC chemokine re-
ceptor 4 (CXCR4) and functions to block CXCR4 and stromal
cell-derived factor-1 (SDF-1) interactions. This blockade results in
Poster Session II S307rapid mobilization of HSCs from niche spaces to peripheral blood.
We hypothesize that AMD3100 creates space within the endogenous
stem cell niche allowing for better engraftment of transplanted HSC
donors.
We found that subcutaneous injections of AMD3100 (5mg/kg)
into C57/BL6-Rag2 common gamma chain-deficient mice induced
mobilization of HSCs from bone marrow and absolute numbers of
HSC in bone marrow reached a nadir four hours post-AMD3100 in-
jection (20136553 vs. 37656392, p 5 0.02, n 5 4-6). AMD3100
pre-treated immunodeficient recipients were transplanted with a bo-
lus dose of 6300 MHC-mismatched AKR/j HSCs. We also per-
formed daily rounds of AMD3100 injections followed by low dose
injections of 450 HSCs over the course of 14 days for a total trans-
plant of 6300 cells. HSC bone marrow donor chimerism 12-weeks
post-transplant was not increased in the bolus-transplanted animals
(1.960.6% vs. 1.460.3%, p5 0.7, n5 5-9). Repeat-transplanted an-
imals exhibited a slight increase in engraftment; however, this in-
crease was not found to be statically significant (2.160.2% vs.
2.560.8%, p 5 0.4, n 5 4-5). These data demonstrate that while
AMD3100 is effective as a HSC mobilizer, it is not effective in
increasing engraftment potential of transplant recipients.421
USE OF UMBILICAL CORD BLOOD IN TRANSPLANTATION FOR PATIENTS
WITH MYELODYSPLASTIC SYNDROME
Bhatla, D.1,Wofford, J.D.2, Regan, D.M.2 1St. Louis University School of
Medicine, St. Louis, MO; 2SSM Cardinal Glennon Children’s Medical
Center, St. Louis, MO
Myelodysplastic Syndrome is a clonal hematological disorder
characterized by peripheral cytopenias with significant risk for pro-
gression to acute myeloid leukemia (AML). It is the most common
hematological malignancy in the elderly with 86% of all MDS diag-
noses reported in individuals over 60 years of age, according to
SEER data. While hypomethylating agents may delay disease pro-
gression and extend overall survival in low riskMDS patients, alloge-
neic hematopoietic stem cell transplant is the only potentially
curative therapy for high risk MDS. The use of umbilical cord blood
as a stem cell source forMDSpatients is attractive because of rapidity
of availability as well as the lower risk of GVHD with increasing
HLA disparity. Outcomes data is limited, but encouraging results
have been reported. This study seeks to examine transplant outcomesTable 1. Data Summary – Single and Dual Cord Blood Trans-
plants
Variable Single Cord Blood Dual Cord Blood
N 24 22
Patient Age
Mean 14.1 44.9
Conditioning Regimen
Myeloablative 21 9
Non-Myeloablative 3 13
ANC Achieved
Yes 24 (100%) 19 (86.4%)
No 0 (0%) 3 (13.6%)
Days to ANC Achieved
Mean 23.3 24.0
Acute GVHD
Yes 17 (70.8%) 4 (18.2%)
No 7 (29.2%) 6 (27.3%)
Unknown 0 (0%) 12 (54.5%)
Chronic GVHD
Yes 6 (25%) 1 (4.5%)
No 16 (66.7%) 8 (36.4%)
Unknown 2 (8.3%) 13 (59.1%)
Survival
Alive 17 (70.8%) 11 (50%)
Expired 7 (29.2%) 11 (50%)
Mean Survival (months) 23.1 11.2of MDS patients receiving umbilical cord blood units from the St.
Louis Cord Blood Bank (SLCBB).
As of September 30, 2010, the SLCBB has shipped units for 95
MDS patients, of which outcomes data is available for 46. Summary
data is provided in the table below for single and dual cord
transplants: Umbilical cord blood is a viable source of stem cells
for HSCT in MDS patients. More data will be required to examine
a possible risk of increased graft vs. host disease with this population.422
KILLER-IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) GENE POLYMOR-
PHISM AND BKV ASSOCIATED HEMORRHAGIC CYSTITIS IN HEMATOPOI-
ETIC STEM CELL TRANSPLANT RECIPIENTS
Askar, M., Mossad, S., Zhang, A., Rybicki, L., Thomas, D., Tench, S.,
Copelan, E., Bolwell, B., Sobecks, R. Cleveland Clinic
Hemorrhagic cystitis (HC) is the most prevalent complication of
BK viruria after allogeneic hematopoietic stem cell transplantation
(HSCT) and is associated with significant morbidity and mortality.
However, why 40–50% of HSCT recipients with persistent viruria
never developHC remains unclear. Killer-immunoglobulin-like Re-
ceptor (KIR) gene polymorphism has been implicated in influencing
clinical outcomes of a number of viruses such as CMV, Hepatitis C,
and HIV.
Objective: To determine whether KIR gene polymorphisms has
a potential role in the development of BKV associated HC after
allogeneic HSCT.
Methods: We performed a retrospective 1:2 matched case-control
study of allogeneic HSCT recipients who underwent transplant at
our institution from 2000-2010. We performed KIR genotyping
for 32 cases with BKV associated HC and 64 matched controls with-
out HC. Two controls were selected for each case, and matched for
disease, preparative regimen, and development of acute GvHD prior
to HC. Recipient KIR genotyping was determined by PCR-rSSOP
(Luminex, One Lambda). Recipient KIR genotype and haplotypes
were assigned as described previously (Middleton andGonzelez, Im-
munology, 2010). The donor’s human leukocyte antigen (HLA) typ-
ing was reviewed from patient charts for determination of KIR
ligands. Conditional logistic regression analysis was used to assess
the association of KIR gene polymorphism and BKV associated
HC. Stepwise analysis using a variable entry criterion of P\ 0.10
and a variable retention criterion of P \ 0.05 was used to assess
multivariable risk factors.
Results:No significant association was identified at the 5% level of
significance between the development of HC and KIR genotypes,
Haplotypes (AA vs. Bx), number of activating receptors, presence
of any particular activating or inhibitory KIRs, or presence of any
cognate HLA ligands.
Conclusion: In contrast to the reported associations between KIR
gene polymorphism and different outcomes of other viruses, our
study does not support a role for KIR gene polymorphism in the
development of BKV associated HC.
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WHY WORK-UP REQUESTS FOR HSCT DONORS FAIL – REASONS AND
WAYS TO IMPROVE FROM A DONOR CENTER PERSPECTIVE
Mengling, T.1, Cotta, L.1, Schmidt, A.H.1, Ehninger, G.2 1DKMS
German Bone Marrow Donor Center, Tuebingen, Germany; 2University
Hospital Carl Gustav Carus, Dresden, Germany
Since 1992, DKMS German Bone Marrow Center has processed
28,672 work-up requests for hematopoietic stem cell donations.
4,328 requests (15.1%) were cancelled by the transplant centers for
patient-related reasons. Of the remaining, 22,840 (93.8%) requests
were successfully completed by collection and transplantation of a vi-
able stem cell product.
Since every work-up is a time and resource intensive process, it is
crucial to minimize the number of futile requests. Therefore, we
have assessed medical and non-medical conditions leading to donor
deferral or temporary unavailability, and identified donor subgroups
more likely to cancel their willingness late in the donor search pro-
cess. Due to the additional costs and loss of time, donors who did
